These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
288 related articles for article (PubMed ID: 17414516)
21. Current controversies in the treatment of high-risk prostate cancer. Mitchell RE; Chang SS Curr Opin Urol; 2008 May; 18(3):263-8. PubMed ID: 18382235 [TBL] [Abstract][Full Text] [Related]
22. Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era. Wagner AD; Moehler M Curr Opin Oncol; 2009 Jul; 21(4):381-5. PubMed ID: 19412098 [TBL] [Abstract][Full Text] [Related]
23. Bone metastases in prostate cancer: a targeted approach. Storey JA; Torti FM Curr Opin Oncol; 2007 May; 19(3):254-8. PubMed ID: 17414645 [TBL] [Abstract][Full Text] [Related]
24. The role of systemic cytotoxic therapy for prostate cancer. Chang SS; Kibel AS BJU Int; 2009 Jan; 103(1):8-17. PubMed ID: 19040524 [TBL] [Abstract][Full Text] [Related]
25. [Targeted therapies for hormone-refractory prostate cancer]. Song HZ; Chen LB Zhonghua Nan Ke Xue; 2010 Dec; 16(12):1108-12. PubMed ID: 21348204 [TBL] [Abstract][Full Text] [Related]
26. The potential role of purine-rich element binding protein (PUR) alpha as a novel treatment target for hormone-refractory prostate cancer. Inoue T; Leman ES; Yeater DB; Getzenberg RH Prostate; 2008 Jul; 68(10):1048-56. PubMed ID: 18386260 [TBL] [Abstract][Full Text] [Related]
27. Novel secondary hormonal therapy in advanced prostate cancer: an update. Van Allen EM; Ryan CJ Curr Opin Urol; 2009 May; 19(3):315-21. PubMed ID: 19342958 [TBL] [Abstract][Full Text] [Related]
30. Is gene therapy the answer for prostate cancer? Patel P; Ashdown D; James N Prostate Cancer Prostatic Dis; 2004 Sep; 7 Suppl 1():S14-9. PubMed ID: 15365577 [TBL] [Abstract][Full Text] [Related]
31. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. Gasparini G; Longo R; Fanelli M; Teicher BA J Clin Oncol; 2005 Feb; 23(6):1295-311. PubMed ID: 15718328 [TBL] [Abstract][Full Text] [Related]
32. Molecular targeting in the treatment of either advanced or metastatic bladder cancer or both according to the signalling pathways. Wallerand H; Reiter RR; Ravaud A Curr Opin Urol; 2008 Sep; 18(5):524-32. PubMed ID: 18670279 [TBL] [Abstract][Full Text] [Related]
34. Prostate cancer treatment strategies based on tumor-specific biological principles: future directions. Carducci MA; DeWeese TL; Nelson WG; Simons JW; Sinibaldi V; Eisenberger MA Semin Oncol; 1996 Dec; 23(6 Suppl 14):56-62. PubMed ID: 8996587 [TBL] [Abstract][Full Text] [Related]
35. Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature. Armstrong AJ; Febbo PG Oncologist; 2009 Aug; 14(8):816-27. PubMed ID: 19684076 [TBL] [Abstract][Full Text] [Related]
36. New drug development in metastatic prostate cancer. Armstrong AJ; George DJ Urol Oncol; 2008; 26(4):430-7. PubMed ID: 18593623 [TBL] [Abstract][Full Text] [Related]
37. Management of prostate cancer. Part 3: metastatic disease. Shah J; Khaksar SJ; Sooriakumaran P Expert Rev Anticancer Ther; 2006 May; 6(5):813-21. PubMed ID: 16759171 [TBL] [Abstract][Full Text] [Related]
38. Clinical endpoints for drug development in prostate cancer. Ramiah V; George DJ; Armstrong AJ Curr Opin Urol; 2008 May; 18(3):303-8. PubMed ID: 18382240 [TBL] [Abstract][Full Text] [Related]